Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study.
Journal
The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
16
10
2020
revised:
19
12
2020
accepted:
21
12
2020
pubmed:
8
2
2021
medline:
4
3
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
To mitigate the COVID-19 pandemic, countries worldwide have enacted unprecedented movement restrictions, physical distancing measures, and face mask requirements. Until safe and efficacious vaccines or antiviral drugs become widely available, viral testing remains the primary mitigation measure for rapid identification and isolation of infected individuals. We aimed to assess the economic trade-offs of expanding and accelerating testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the USA in different transmission scenarios. We used a multiscale model that incorporates SARS-CoV-2 transmission at the population level and daily viral load dynamics at the individual level to assess eight surveillance testing strategies that varied by testing frequency (from daily to monthly testing) and isolation period (1 or 2 weeks), compared with the status-quo strategy of symptom-based testing and isolation. For each testing strategy, we first estimated the costs (incorporating costs of diagnostic testing and admissions to hospital, and salary lost while in isolation) and years of life lost (YLLs) prevented under rapid and low transmission scenarios. We then assessed the testing strategies across a range of scenarios, each defined by effective reproduction number (R Our modelling showed that daily testing combined with a 2-week isolation period was the most costly strategy considered, reflecting increased costs with greater test frequency and length of isolation period. Assuming a societal willingness to pay of US$100 000 per YLL averted and a price of $5 per test, the strategy most likely to be cost-effective under a rapid transmission scenario (R Extensive expansion of SARS-CoV-2 testing programmes with more frequent and rapid tests across communities coupled with isolation of individuals with confirmed infection is essential for mitigating the COVID-19 pandemic. Furthermore, resources recouped from shortened isolation duration could be cost-effectively allocated to more frequent testing. US National Institutes of Health, US Centers for Disease Control and Prevention, and Love, Tito's.
Sections du résumé
BACKGROUND
To mitigate the COVID-19 pandemic, countries worldwide have enacted unprecedented movement restrictions, physical distancing measures, and face mask requirements. Until safe and efficacious vaccines or antiviral drugs become widely available, viral testing remains the primary mitigation measure for rapid identification and isolation of infected individuals. We aimed to assess the economic trade-offs of expanding and accelerating testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the USA in different transmission scenarios.
METHODS
We used a multiscale model that incorporates SARS-CoV-2 transmission at the population level and daily viral load dynamics at the individual level to assess eight surveillance testing strategies that varied by testing frequency (from daily to monthly testing) and isolation period (1 or 2 weeks), compared with the status-quo strategy of symptom-based testing and isolation. For each testing strategy, we first estimated the costs (incorporating costs of diagnostic testing and admissions to hospital, and salary lost while in isolation) and years of life lost (YLLs) prevented under rapid and low transmission scenarios. We then assessed the testing strategies across a range of scenarios, each defined by effective reproduction number (R
FINDINGS
Our modelling showed that daily testing combined with a 2-week isolation period was the most costly strategy considered, reflecting increased costs with greater test frequency and length of isolation period. Assuming a societal willingness to pay of US$100 000 per YLL averted and a price of $5 per test, the strategy most likely to be cost-effective under a rapid transmission scenario (R
INTERPRETATION
Extensive expansion of SARS-CoV-2 testing programmes with more frequent and rapid tests across communities coupled with isolation of individuals with confirmed infection is essential for mitigating the COVID-19 pandemic. Furthermore, resources recouped from shortened isolation duration could be cost-effectively allocated to more frequent testing.
FUNDING
US National Institutes of Health, US Centers for Disease Control and Prevention, and Love, Tito's.
Identifiants
pubmed: 33549196
pii: S2468-2667(21)00002-5
doi: 10.1016/S2468-2667(21)00002-5
pmc: PMC7862022
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e184-e191Subventions
Organisme : CDC HHS
ID : U01P001136-01-01
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI141576
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001136
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001137
Pays : United States
Organisme : CDC HHS
ID : CDC-HHS-6U01IP001137-01
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI151176
Pays : United States
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
N Engl J Med. 2014 Aug 28;371(9):796-7
pubmed: 25162885
Nat Hum Behav. 2020 Sep;4(9):964-971
pubmed: 32759985
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1631-1634
pubmed: 33151916
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515
pubmed: 32632012
BMJ. 2020 Dec 15;371:m4704
pubmed: 33323388
Lancet. 2020 Nov 7;396(10261):1525-1534
pubmed: 32979936
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Nat Commun. 2021 Jan 12;12(1):323
pubmed: 33436609
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634